Hemostasis Today
NewsFeed
Headlines Hematology Health Medicine VTE ASH Plasma Donation
October, 2026
October 2026
M T W T F S S
 1234
567891011
12131415161718
19202122232425
262728293031  
Wolfgang Miesbach: Predicting Breakthrough Bleeding in Emicizumab-Treated Acquired Haemophilia A
Wolfgang Miesbach/LinkedIn
Dec 18, 2025, 23:23

Wolfgang Miesbach: Predicting Breakthrough Bleeding in Emicizumab-Treated Acquired Haemophilia A

Wolfgang Miesbach, Professor of Medicine at Frankfurt University Hospital, shared on LinkedIn:

“Predicting Breakthrough Bleeding in Emicizumab-Treated Acquired Haemophilia A. Excellent work presented at ASH2025 by Fabius Pelzer addressing one of the most pressing challenges in acquired haemophilia A:
Despite emicizumab’s remarkable efficacy in preventing bleeds, up to 30% of patients still experience breakthrough bleeding—and we currently lack reliable predictive tools to identify who’s at risk.

Wolfgang Miesbach: Predicting Breakthrough Bleeding in Emicizumab-Treated Acquired Haemophilia A

This changes today.

Using FXIa-triggered thrombin generation (FXIa-TGA) as a surrogate biomarker, Pelzer and colleagues developed an innovative nomogram to assess individual bleeding risk based on:

  • Peak thrombin generation potential
  • Emicizumab levels
  • Residual Factor VIII activity

Main findings:

  • FXIa-TGA peak thrombin is more sensitive than conventional TGA to low factor levels and emicizumab concentrations
  • Both emicizumab and residual Factor VIII significantly influence peak thrombin generation in the multivariable model
  • Higher peak thrombin values correlated with lower bleeding rates (IRR 0.40 [0.17-0.84])

This is precision haemostasis and enables patient-specific risk stratification in real time. Moving beyond one-size-fits-all dosing to truly personalized management of AHA.

Wolfgang Miesbach: Predicting Breakthrough Bleeding in Emicizumab-Treated Acquired Haemophilia A

Having a functional biomarker that predicts individual risk opens pathways for:

  • Optimized prophylactic dosing strategies
  • Early detection of patients requiring intervention
  • Better understanding of emicizumab mechanism in real-world AHA

Congratulations to Fabius, Andreas Tiede and the entire GTH study team on this rigorous work that has now been published in Haematologica Journal.”

Read more posts from Wolfgang Miesbach on Hemostasis Today.

American Society of Hematology (ASH) Andreas Tiede ASH2025 ASH25 bleeding Emicizumab Fabius Pelzer Factor VIII FXIa Haematologica Journal haemophilia A Health Hematology Hemostasis Hemostasis Today Medicine thrombosis Wolfgang Miesbach
NewsFeed